GenScript Subsidiary ProBio Instrumental in Latest Fight Against Cancer
November 16, 2024
November 16, 2024
PISCATAWAY, New Jersey, Nov. 16 -- GenScript, a biotech company that provides life sciences services and products to scientists, issued the following news release on Nov. 15, 2024:
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck . . .
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck . . .